AndzonBio2, University of Cambridge, and Cambridge Enterprise Collaborate on Neuroinflammation Therapeutics

AndzonBio2 has partnered with the ALBORADA Drug Discovery Institute at the University of Cambridge and Cambridge Enterprise to develop new therapeutics for neuroinflammation. These conditions drive neurodegenerative diseases like Parkinson's and Alzheimer's, affecting over 3 billion individuals globally. Current treatments are limited, highlighting the need for innovative solutions targeting neuroinflammation.

The partnership will leverage AndzonBio2's expertise in drug development and Cambridge's neuroscience capabilities. The collaboration focuses on a novel therapeutic program aimed at modulating neuroinflammatory pathways, based on cutting-edge biological research.

Cambridge Enterprise grants AndzonBio2 exclusive licensing rights to any resulting intellectual property. This approach intends to integrate academic discoveries with industrial drug development for swift progress. The collaboration highlights Cambridge's commitment to converting neuroscience innovations into practical therapies.